Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency  by Mackie, Fiona E. et al.
Kidney International, Vol. 61 (2002), pp. 555–563
VASCULAR BIOLOGY – HEMODYNAMICS – HYPERTENSION
Effects of antihypertensive therapy on intrarenal angiotensin
and bradykinin levels in experimental renal insufficiency
FIONA E. MACKIE, TIMOTHY W. MEYER, and DUNCAN J. CAMPBELL
Division of Nephrology, VA Palo Alto Health Care System and Stanford University, Palo Alto, California, USA,
and St. Vincent’s Institute of Medical Research, Fitzroy; and the University of Melbourne Department of Medicine,
Victoria, Australia
Effect of antihypertensive therapy on intrarenal angiotensin and Angiotensin-converting enzyme (ACE) inhibitors slow
bradykinin levels in experimental renal insufficiency. the progression of renal disease to a greater extent than
Background. Whereas angiotensin converting enzyme inhibi- alternate antihypertensive treatment despite equivalenttors and angiotensin type 1 receptor antagonists have beneficial
blood pressure reduction [2]. Moreover, the equivalenteffects in the remnant model of renal failure, calcium channel
effects of angiotensin (Ang) II type 1 (AT1) receptorblockers do not consistently improve renal disease in this model.
This study examined whether these different means of blood blockade and ACE inhibition in preventing renal disease
pressure reduction have different effects on renal levels of angio- in animal [3, 4] and human studies [5, 6] suggest an
tensin (Ang) and bradykinin peptides. important role for Ang II in the pathogenesis of renalMethods. Rats subjected to five-sixths nephrectomy were
disease [7]. In contrast, despite effective blood pressuredivided into groups with similar hypertension and proteinuria
control, calcium channel blockers do not consistentlyat 4 to 5 weeks. They then received either no treatment, or
enalapril, losartan or nifedipine for 2 weeks. Following repeat slow the decline of renal function or decrease proteinuria
measurements of proteinuria and blood pressure, Ang II and in human studies [8–10].
bradykinin peptides were measured in the remnant kidney and Results obtained in rats subjected to renal ablation,renin, Ang II, and aldosterone were measured in the plasma.
for the most part, are consistent with those obtained inResults. All three drugs had equivalent blood pressure-lower-
human studies. Converting enzyme inhibition and AT1ing effects. Enalapril and losartan reduced proteinuria but
nifedipine did not. Reduction of proteinuria in rats treated receptor antagonists repeatedly have been shown to nor-
with enalapril and losartan was associated with a reduction in malize blood pressure, reduce proteinuria and prevent glo-
Ang II levels in both the peri-infarct and intact portions of the merular injury in this model [3, 7, 11]. In contrast, calciumremnant kidney. By contrast, nifedipine increased Ang II levels
channel blockade generally has been found to have lessin the intact portion of the remnant kidney. Losartan reduced
if any beneficial effect [12–14]. A number of reasons havebradykinin levels in the peri-infarct portion of the remnant kid-
ney while enalapril reduced bradykinin levels in the intact por- been proposed for the lack of beneficial effect of calcium
tion of the remnant kidney. Nifedipine had no effect on intra- channel blockade, including altered autoregulation of
renal bradykinin levels. the afferent arteriole, inconsistent blood pressure reduc-Conclusions. The differential effects of enalapril, losartan
tion and failure to modify the intrarenal effects of Angand nifedipine on proteinuria and intrarenal Ang II and brady-
II [13, 15]. The goal of the current study was to determinekinin levels suggest that the ability of an antihypertensive to
decrease proteinuria may depend on its ability to decrease if the effects of different antihypertensive agents on pro-
kidney Ang II and bradykinin levels. teinuria in the renal ablation model could be related to
their effects on intrarenal Ang II and bradykinin levels.
We compared the effects of enalapril, an ACE inhibitor,Whereas effective control of hypertension slows the
with losartan, an AT1 receptor antagonist, and nifedi-decline of renal function in progressive renal disease [1],
pine, a dihydropyridine calcium channel antagonist, onsome antihypertensive agents offer more effective pro-
renal peptide levels and circulating components of thetection than expected from blood pressure reduction.
renin-angiotensin-aldosterone system (RAAS).
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Accepted for publication September 5, 2001 kidney and ligation of the arterial branches supplying 2/3
of the left kidney as previously described [16]. All animal 2002 by the International Society of Nephrology
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experiments were carried out according to protocols ap- of measurement on two non-consecutive 24-hour urine
proved by the institutional animal care committee. Two collections assayed with the Coomassie blue method.
experiments were performed. In the first, enalapril treat- Blood pressure and urine protein measurements were
ment was compared to losartan or no treatment. Five not made on the day prior to decapitation in order to
weeks after reduction of renal mass, rats were divided reduce stress on the animals.
into three groups with similar values for body weight, sys-
Measurement of angiotensin and bradykinin peptidestolic blood pressure, and proteinuria. Group 1 (N  7)
continued to receive no treatment while Group 2 (N  9) Pieces of fresh kidney were immediately homogenized
received enalapril 50 mg/L in drinking water and Group 3 in 10 mL of 4 mol/L guanidine thiocyanate/1%-trifluoro-
(N  9) received losartan 180 mg/L in drinking water. acetic acid. After centrifugation the supernatant was ap-
Blood pressure and proteinuria were measured again plied to Sep-Pak C18 cartridges (Waters Chromatogra-
after two weeks and rats were then sacrificed for mea- phy, Milford, MA, USA) and extraction and subsequent
surements of plasma renin, angiotensin peptides and al- processing performed as described previously [18]. The
dosterone, as well as kidney angiotensin and bradykinin dried angiotensin and bradykinin peptides were acetylated
peptides. In the second experiment nifedipine treatment
and treated with piperidine before high performance liq-
was compared to enalapril or no treatment. Four weeks
uid chromatography and subsequent N-terminal directedafter renal mass was reduced, body weight, systolic blood
radioimmunoassay (RIA). Data were corrected for re-pressure, and proteinuria were measured and the rats
covery as reported previously [19]. Trunk blood for plasmadivided into three treatment groups: Group 1 (N  17)
Ang I and Ang II was collected into tubes containingwas untreated; Group 2 (N  16) received enalapril 25
0.5 mL inhibitor solution [1 mmol/L renin inhibitor, ace-mg/L in drinking water; Group 3 (N  17) received the
tyl-His-Pro-Phe-Val-Sta-Leu-Phe-NH2 [20], 146 mol/Llong acting formulation of nifedipine (Bayer Corpora-
pepstatin, 50 mmol/L 1,10 phenathroline, 125 mmol/Ltion, Tarrytown, NY, USA) 0.07% mixed in powdered
ethylenediaminetetra-acetate (EDTA), 2 g/L neomycinrat chow. The dose of nifedipine required to lower blood
sulfate, 2% dimethyl sulfoxide (DMSO), and 2% etha-pressure to an equivalent degree as enalapril was deter-
nol]. After centrifugation the plasma was immediatelymined in a pilot experiment. Because of the requirement
extracted with Sep-Pak C18 cartridges and dried samplesto administer nifedipine in powdered rat chow, in the
were processed as described for the kidney samples.second experiment all animals were placed on a normal
powdered rat chow diet five days before being divided
Measurement of PRA and aldosteroneinto treatment groups and were maintained on powdered
rat chow during the treatment period. Trunk blood was collected into heparinized tubes, cen-
Rats in all groups were killed by decapitation at the trifuged at 1600  g and stored at 40C until analysis.
close of the study. Trunk blood was collected and the Ten microliters of 0.5 mol/L EDTA, 8 g of dimercaprol
kidneys were then rapidly removed for tissue hormone and 0.3 mg of 8 hydroxyquinoline were added to 100 L
analysis. Remnant kidneys were cut with a razor blade of plasma sample before PRA measurement to inhibit
into three weighed pieces prior to analysis. One piece, angiotensinases. PRA was measured by the generation
denoted the “intact portion,” included only tissue distant of Ang I after three hours incubation at 37C and subse-
from the infarct borders. A second piece (denoted the quent RIA using a commercially available kit (NEN Life
“peri-infarct portion”) was cut to include the infarct and Sciences, Boston, MA, USA). Aldosterone was mea-
its borders. The third piece consisting of the remaining sured by RIA using a commercially available kit (Coat-
kidney tissue was discarded. The purpose of dividing the A-Count; Diagnostic Products Corporation, Los Angeles,
remnant kidney was to separate areas of high and low
CA, USA). Kidneys for renin analysis were cut into peri-
renin content as described by Correa-Rotter et al [17]. In
infarct and intact portions as described above. They werethe first experiment, angiotensin and bradykinin peptides
then homogenized in a protease-inhibiting buffer con-were measured in the kidney and plasma renin activity
taining EDTA, dimercaprol, phenylmethylsulfonyl flu-(PRA), and the angiotensin peptides and aldosterone
oride (PMSF), 8-OH-quinoline sulfate and ammoniumwere measured in the plasma. In the second experiment
acetate. Kidney renin concentration was measured in thetwo cohorts of animals were used. In the first cohort,
supernatant of the kidney homogenates after performingangiotensin and bradykinin peptides were measured in
three freeze thaw cycles and a 1:1000 dilution with prote-the kidney and PRA, angiotensin peptides and aldoste-
ase inhibiting buffer. Aliquots of diluted tissue homoge-rone were measured in the plasma. In the second cohort,
nate were then incubated at 37C for two hours withrenin content was measured in the kidney.
excess renin substrate in the form of nephrectomized ratSystolic blood pressure was determined as the mean of
plasma, and Ang I generation was quantified by RIA.five individual measurements using the tail cuff method.
Urine protein excretion was determined as the mean Values are expressed per gram of kidney tissue.
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Table 1. Body weight (BW), systolic blood pressure (SBP), and proteinuria (UproV) in remnant rats before and
after 2 weeks of antihypertensive treatment (Rx)
BW Pre-Rx BW Post-Rx SBP Pre-Rx Final SBP UproV Pre-Rx UproV Post-Rx
g mm Hg mg/day
Experiment 1
Untreated N7 2927 2948 1933 1979 15222 18416
Enalapril N9 2874 3011 1836 1425a,c 12515 6010a,c
Losartan N9 2807 2935 1897 1256a,c 17025 7613a,c
Experiment 2
Untreated N17 2743 2876 2055 2176 12320 15217
Enalapril N16 2704 2906 2007 1563a,c 12413 729a,c
Nifedipine N17 2765 2958 1927 1465a,c 11515 18120b,c
Values are mean  SEM.
a P  0.05 vs. untreated
b P  0.05 vs. enalapril
c P  0.05 vs. before treatment
Statistical analysis Plasma renin, aldosterone, and angiotensin peptides
Data are presented as means SEM. Statistical analy- Measurements of circulating renin-angiotensin-aldo-
sis was performed by analysis of variance (ANOVA) sterone components are summarized in Table 2. In exper-
with Fisher’s protected least significant difference (PLSD) iment 1, enalapril and losartan caused similar increases
test. Parameters measured before and after treatment in PRA and Ang I levels. Losartan, but not enalapril,
and between peri-infarct and intact portions of each increased plasma Ang II levels and enalapril, but not
treatment group were compared using the paired t test. losartan, decreased the plasma Ang II/Ang I ratio, which
Logarithmic transformation of the data was performed provides an index of the rate of conversion of Ang I to
when required to obtain similar variances among groups. Ang II. Neither treatment altered aldosterone levels. In
Two-way ANOVA was used to assess the effect of enala- experiment 2, enalapril and nifedipine increased PRA
pril on bradykinin levels between the two experiments. levels. Enalapril, but not nifedipine, caused a significant
The software package Statview 5.0 (Abacus Concepts, increase in plasma Ang I levels and a reduction in the
Inc., Berkeley, CA, USA) was used for analyses. A P plasma Ang II/Ang I ratio. Neither drug significantly
value of 0.05 was considered statistically significant. altered plasma levels of Ang II or aldosterone.
Kidney renin concentrationRESULTS
Kidney renin concentration was measured in experi-Blood pressure, proteinuria, body weight and
ment 2. The concentrations of renin observed in theplasma creatinine
intact and peri-infarct portions of the remnant kidney
Body weight, systolic blood pressure, and proteinuria are depicted in Figure 1. The renin content in the peri-
are presented in Table 1. Body weight, systolic blood infarct portion was higher by severalfold than in the
pressure and urinary protein excretion were matched in
intact portion of the kidney in the enalapril and un-
the treatment groups before drug administration. Treat-
treated groups. Treatment with either enalapril or nifedi-ment with enalapril, losartan or nifedipine did not affect
pine did not significantly increase it further. Both enala-body weight, which was not significantly different from
pril and nifedipine increased renin content in the intactuntreated controls in both experiments. As expected, rats
portion of the remnant kidney.subjected to renal ablation developed hypertension and
proteinuria. In experiment 1, treatment with either enala- Kidney angiotensin peptides
pril or losartan caused a reduction in blood pressure that
Angiotensin I and Ang II peptides and the Ang II/was not significantly different between the two groups.
Ang I ratio in the intact and peri-infarct portions of theIn experiment 2, treatment with enalapril or nifedipine
remnant kidney for both experiments are presented incaused similar reductions in blood pressure. In both ex-
Figure 2. Ang I levels were higher in the peri-infarctperiments, reduction of blood pressure with enalapril
than in the intact portion of the remnant kidney of allwas associated with significant reduction in proteinuria.
groups for both experiments, and Ang II levels wereLosartan treatment was associated with a significant re-
higher in the peri-infarct portion in the untreated andduction in proteinuria, similar to that seen with enalapril.
nifedipine treated rats of experiment 2. Enalapril hadIn contrast, in experiment 2 the reduction of blood pres-
similar effects on kidney angiotensin peptide levels insure with nifedipine was accompanied by a significant
rise in urinary protein excretion. experiments 1 and 2. Both enalapril and losartan reduced
Mackie et al: Efficacy of antihypertensive therapies558
Table 2. Components of the circulating renin angiotensin aldosterone system after two weeks of antihypertensive treatment
Ang I Ang II Ang II/Ang I ratio
PRA Aldosterone
ng Ang I/mL/hr pg/mL fmol/mL fmol/fmol
Experiment 1
Untreated N5–7 0.30.1 11638 31 103 5.61.6
Enalapril N6–9 103a 15427 6215a 41 0.20.1a
Losartan N6–9 102a 17441 6924a 15532a,b 3.90.9b
Experiment 2
Untreated N8–9 0.80.1 14046 51 167 4.00.8
Enalapril N9–10 8.32.7a 11347 5513a 3921 0.80.4a
Nifedipine N10–11 4.21.4a 328214 104b 122 2.91.3b
Values are mean  SEM. Abbreviations are: REM, remnant; PRA, plasma renin activity; Ang, angiotensin.
a P  0.05 vs. untreated
b P  0.05 vs. enalapril
for the untreated, enalapril, and losartan treated rats of
experiment 1. However, the levels of BK (1-7) and BK
(1-9) in the intact portion were much higher in experi-
ment 2 than in experiment 1, with a smaller difference
in bradykinin peptide levels between peri-infarct and
intact portions in experiment 2. Enalapril reduced BK
(1-9) levels in the peri-infarct portion in experiment 1,
but the effects of enalapril on kidney kinin levels were
not statistically significant in experiment 2. When the
effects of enalapril in experiments 1 and 2 were analyzed
together by two-way ANOVA, enalapril reduced BK
(1-9) levels (P 0.02) in the intact portion, and increased
the BK (1-7)/BK (1-9) ratio (P 0.03) in the peri-infarct
portion of the remnant kidney. Losartan reduced BK
(1-7) levels in the intact portion and both BK (1-7) and
Fig. 1. Kidney renin concentration in experiment 2. Symbols are: () BK (1-9) levels in the peri-infarct portion, associated
intact portion of the remnant kidney; () peri-infarct portion of the
with an increase in the BK (1-7)/BK (1-9) ratio in theremnant kidney. *P  0.05 vs. corresponding region of untreated rats;
P  0.01 peri-infarct vs. intact portion. Data are shown as mean  peri-infarct portion of the remnant kidney. By contrast,
SEM and N  6 to 8 in each group. nifedipine did not modify renal bradykinin levels.
DISCUSSION
Ang II levels in both the peri-infarct and intact portions
In accord with previous studies, enalapril and losartanof the remnant kidney. Neither drug affected Ang I levels
lowered blood pressure and proteinuria in rats subjectedin the kidney, whereas both drugs reduced the Ang II/
to renal ablation. Nifedipine treatment, despite an equiv-Ang I ratio in the peri-infarct portion. Losartan also
alent blood pressure lowering effect, did not reduce pro-reduced the Ang II/Ang I ratio in the intact portion. By
teinuria. The different effects of the drugs on proteinuriacontrast, nifedipine increased Ang II levels in the intact
were associated with differences in their effects on intra-portion to a level significantly greater than both the un-
renal peptide levels. Enalapril and losartan reduced renaltreated and enalapril treated rats. Ang I levels were not
Ang II levels while nifedipine increased these levels. Inaltered and there was an increase in the Ang II/Ang I
addition, losartan, and to a lesser extent enalapril, reducedratio in the intact portion with nifedipine treatment.
intrarenal bradykinin levels. These findings support a pri-
Kidney bradykinin peptides mary role for Ang II in remnant glomerular injury, and
suggest further that Ang II may stimulate increased activ-The concentration of BK (1-9) and its metabolite BK
ity of the intrarenal kallikrein kinin system in the rem-(1-7) observed in renal tissue are shown in Figure 3. The
nant kidney. Moreover, these data suggest that bradykininBK (1-7)/BK (1-9) ratio gives an indication of the rate
may mediate in part the actions of Ang II in this condition.of metabolism of BK (1-9) to BK (1-7) by ACE and
Our findings regarding the effects of nifedipine andother peptidases including neutral endopeptidase. Both
enalapril on remnant glomerular injury are consistentBK (1-7) and BK (1-9) levels were higher in the peri-
infarct than in the intact portion of the remnant kidney with those of Griffin, Picken and Bidani [14]. They showed
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Fig. 2. Kidney angiotensin II (Ang II), Ang I and Ang II/Ang I ratio in experiments 1 and 2. Symbols are: () intact portion of the remnant
kidney; () peri-infarct portion of the remnant kidney. *P  0.05 vs. corresponding region of untreated rats; **P  0.01 vs. corresponding region
of untreated rats; P  0.05 peri-infarct vs. intact portion; P  0.01 peri-infarct vs. intact portion; #P  0.05 vs. enalapril treated rats; ##P 
0.01 vs. enalapril treated rats. Data are shown as mean  SEM and N  7 to 11 in each group.
that in comparison with enalapril, nifedipine caused a effects of these blood pressure-reducing agents. In con-
trast to enalapril and losartan, lowering the pressure withshift to the left and a steepening of the glomerulosclerosis
score/blood pressure relationship that was associated nifedipine was associated with an increase in Ang II
levels in the intact functioning portion of the remnantwith additional impairment of the already impaired renal
autoregulation in the remnant kidney. At any given kidney. The increase in Ang II levels in the intact portion
of the remnant kidney was associated with an increaseblood pressure, rats receiving nifedipine manifested
more glomerular injury than rats receiving enalapril. in the Ang II/Ang I ratio, suggesting that nifedipine may
have increased renal ACE activity, thus contributing toMeasurement of intrarenal Ang II levels in our current
study provides a possible explanation for the different increased Ang II levels in this region of the remnant
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Fig. 3. Kidney bradykinin (1-7) [BK (1-7)], BK (1-9) and BK (1-7)/(1-9) ratio in experiments 1 and 2. Symbols are: () intact portion of the
remnant kidney; () peri-infarct portion of the remnant kidney. *P  0.05 vs. corresponding region of untreated rats; **P  0.01 vs. corresponding
region of untreated rats; P  0.05 peri-infarct vs. intact portion; P  0.01 peri-infarct vs. intact portion; #P  0.05 vs. enalapril treated rats.
Data are shown as mean  SEM and N  7 to 11 in each group.
kidney. The increase in PRA with nifedipine treatment In a previous study, we found that the remnant kidney
model is associated with transient increases in peri-may have been a response to the fall in blood pressure,
leading to increased renin secretion from the ischemic infarct kidney Ang II levels and plasma Ang II and aldo-
sterone levels at two weeks [21]. However, plasma Angportions of the remnant kidney. However, we are unable
to explain the lack of increase in plasma angiotensin II and aldosterone, as well as peri-infarct Ang II levels
were not higher than in control rats at 5 and 7 weekspeptide levels in nifedipine-treated rats. The levels of
plasma angiotensin peptides are determined by both following renal ablation. Moreover, Ang II levels in the
intact portion of the remnant kidney were not highertheir rate of production and rate of degradation. We did
not examine Ang II degradation in these experiments, than in the kidney of control rats. This finding, along
with the finding of Verhagen et al [22] of normal Angand further experiments would be necessary to address
whether changes in Ang II degradation contributed to II levels in the kidneys of rats made hypertensive by
nitric oxide synthase inhibition, indicates that an increasethe failure of plasma Ang II levels to rise with nifedipine.
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in intrarenal Ang II content above normal is not neces- renal Ang II levels in the peri-infarct and intact portions
sary for the development of injury in intact renal tissue of the remnant kidney. The mechanism by which both
in the setting of high blood pressure. ACE inhibition and AT1 receptor blockade reduce intra-
The remnant kidney model is complex and involves renal Ang II levels remains to be conclusively estab-
many pathological processes in addition to reduction in lished. We previously showed that reduction in kidney
nephron number. The increase in blood pressure and Ang II levels with perindopril in normal rats was not
development of glomerular injury are in general more accompanied by a rise in Ang I levels [29]. Furthermore,
severe when nephron number is reduced by partial in- there was a reduction in kidney angiotensinogen levels
farction of the kidney than by excision of renal tissue suggesting that local consumption of angiotensinogen
[23, 24]. One potential mechanism is by promoting an occurred due to a large increase in renin secretion. We
increase in glomerular capillary pressure. Presumably therefore proposed that local consumption of angioten-
increased intrarenal Ang II levels could account for the sinogen limits any increase in renal angiotensin peptide
finding that glomerular pressure remains high when levels during perindopril administration [29]. We have
blood pressure in rats subjected to renal ablation is low- shown previously that losartan reduced Ang II levels in
ered by the “triple therapy” antihypertensive combina- the normal kidney [30], which may be due to a similar
tion of reserpine, hydralazine and thiazide [11]. In addi- mechanism. Moreover, losartan may prevent renal uptake
tion to hemodynamic effects, Ang II may promote of Ang II by blockade of the AT1 receptor as demonstrated
glomerulosclerosis by stimulating expression of trans- in rats infused with an exogenous form of Ang II [31].
forming growth factor-	 (TGF-	) and platelet-derived In addition, losartan reduced the Ang II/Ang I ratio in
growth factor-	 (PDGF-	) [25]. There is also evidence the remnant kidney, indicating that losartan may have
that Ang II may directly promote tubulointerstitial injury reduced Ang I conversion to Ang II, possibly by reducing
in the remnant kidney. Inflammatory phenomena such as renal ACE activity. We previously observed that losartan
macrophage and lymphocyte infiltration, together with administration reduced the renal Ang II/Ang I ratio in
tubulointerstitial myofibroblast transdifferentiation and normal rats [30].
tubulointerstitial cell proliferation, have been implicated We previously showed marked increases in bradykinin
in tubulointerstitial injury [26]. Recent studies show that peptide levels in the intact and peri-infarct portions of
increased Ang II levels can promote renal inflammation the remnant kidney [21]. In addition to reducing Ang II
by stimulating monocyte and macrophage infiltration levels, losartan reduced bradykinin levels in the peri-
[27]. Gilbert et al reported that intrarenal renin and Ang infarct portion and enalapril reduced levels in the intact
II content are predominant in renal tubular epithelial portion of the remnant kidney. We propose that the
cells of the remnant kidney at 12 weeks after renal abla-
decrease in intrarenal bradykinin levels in response to
tion [28]. These authors suggest that renin and Ang II
losartan and enalapril was due to the suppression of thecontent in tubular epithelial cells may be pathogenically
Ang II-dependent inflammatory processes by these drugs.involved in the progressive tubulointerstitial injury of
There has been some debate as to the role of bradykinin inthis condition. However, it is not known whether tubular
mediating the renoprotective actions of ACE inhibition,epithelial expression of renin and Ang II occurs at the
with reports that bradykinin type 2 (B2) receptor antago-earlier time after renal ablation examined in the present
nists do not modify the effects of ACE inhibition [32].study. Gilbert et al also noted that ACE inhibition pre-
Our demonstration that losartan and enalapril actuallyvents tubular epithelial expression of renin and Ang II,
decrease intrarenal bradykinin levels provides an expla-suggesting that renin and Ang II content in the renal
nation for the failure of B2 receptor antagonism to mod-tubular epithelium is secondary to Ang II-dependent
ify the effects of ACE inhibition. The reduction in intra-pathogenic processes in the remnant kidney [28].
renal bradykinin levels in response to enalapril was inAn interesting finding of the current study was that
contrast to our earlier studies in normal rats where in-losartan as well as enalapril reduced intrarenal Ang II
flammation was absent and ACE inhibition increasedlevels. The doses of enalapril and losartan used caused
bradykinin levels by inhibiting bradykinin metabolismsimilar reductions in blood pressure and similar increases
[18, 33]. We previously showed that losartan reducedin PRA and plasma Ang I levels. Whereas converting
intrarenal bradykinin levels in normal rats [30], a findingenzyme inhibition reduced the plasma Ang II/Ang I ratio
that suggests that intrarenal bradykinin levels are subjectso that the increase in plasma Ang I level was not accom-
to tonic stimulation by Ang II acting through the AT1panied by an increase in Ang II level, AT1 receptor
receptor. Our findings are in contrast to the studies ofblockade did not affect the plasma Ang II/Ang I ratio
Siragy, de Gasparo and Carey, who found that AT1 re-and the plasma Ang II level increased in parallel with
ceptor antagonism increased immunoreactive bradyki-the plasma Ang I level in rats given losartan. However,
nin levels in microdialysate fluid from the rat kidneythe pattern of changes in intrarenal angiotensin peptides
was different from that in plasma. Both agents reduced [34]. The difference between our data and those of Siragy
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